Back to Search Start Over

Papain grafted into the silica coated iron-based magnetic nanoparticles 'IONPs@SiO 2 -PPN' as a new delivery vehicle to the HeLa cells.

Authors :
Nasiri R
Dabagh S
Meamar R
Idris A
Muhammad I
Irfan M
Rashidi Nodeh H
Source :
Nanotechnology [Nanotechnology] 2020 May 08; Vol. 31 (19), pp. 195603. Date of Electronic Publication: 2020 Jan 24.
Publication Year :
2020

Abstract

The present study aims at engineering, fabrication, characterization, and qualifications of papain (PPN) conjugated SiO <subscript>2</subscript> -coated iron oxide nanoparticles 'IONPs@SiO <subscript>2</subscript> -PPN'. Initially fabricated iron oxide nanoparticles (IONPs) were coated with silica (SiO <subscript>2</subscript> ) using sol-gel method to hinder the aggregation and to enhance biocompatibility. Next, PPN was loaded as an anticancer agent into the silica coated IONPs (IONPs@SiO <subscript>2</subscript> ) for the delivery of papain to the HeLa cancer cells. This fabricated silica-coated based magnetic nanoparticle is introduced as a new physiologically-compatible and stable drug delivery vehicle for delivering of PPN to the HeLa cancer cell line. The IONPs@SiO <subscript>2</subscript> -PPN were characterized using FT-IR, AAS, FESEM, XRD, DLS, and VSM equipment. Silica was amended on the surface of iron oxide nanoparticles (IONPs, γ-Fe <subscript>2</subscript> O <subscript>3</subscript> ) to modify its biocompatibility and stability. The solvent evaporation method was used to activate PPN vectorization. The following tests were performed to highlight the compatibility of our proposed delivery vehicle: in vitro toxicity assay, in vivo acute systemic toxicity test, and the histology examination. The results demonstrated that IONPs@SiO <subscript>2</subscript> -PPN successfully reduced the IC <subscript>50</subscript> values compared with the native PPN. Also, the structural alternations of HeLa cells exposed to IONPs@SiO <subscript>2</subscript> -PPN exhibited higher typical hallmarks of apoptosis compared to the cells treated with the native PPN. The in vivo acute toxicity test indicated no clinical signs of distress/discomfort or weight loss in Balb/C mice a week after the intravenous injection of IONPs@SiO <subscript>2</subscript> (10 mg kg <superscript>-1</superscript> ). Besides, the tissues architectures were not affected and the pathological inflammatory alternations detection failed. In conclusion, IONPs@SiO <subscript>2</subscript> -PPN can be chosen as a potent candidate for further medical applications in the future, for instance as a drug delivery vehicle or hyperthermia agent.

Details

Language :
English
ISSN :
1361-6528
Volume :
31
Issue :
19
Database :
MEDLINE
Journal :
Nanotechnology
Publication Type :
Academic Journal
Accession number :
31978907
Full Text :
https://doi.org/10.1088/1361-6528/ab6fd4